Proinflammatory cytokine gene polymorphisms and susceptibility to Paget's disease of bone: an association study.

[1]  R. González-Sarmiento,et al.  Paget's disease of bone is not associated with common polymorphisms in interleukin-6, interleukin-8 and tumor necrosis factor alpha genes. , 2010, Cytokine.

[2]  D. James,et al.  Paget's Disease , 2009, Journal of medical biography.

[3]  R. Altman.  Paget’s Disease of Bone , 2008 .

[4]  I. Reid,et al.  Pathogenesis and management of Paget's disease of bone , 2008, The Lancet.

[5]  R. Layfield,et al.  Ubiquitin-mediated signalling and Paget's disease of bone , 2007, BMC Biochemistry.

[6]  R. Layfield.  The molecular pathogenesis of Paget disease of bone , 2007, Expert Reviews in Molecular Medicine.

[7]  W. Fraser,et al.  Detection of hearing impairment and handicap in Paget's disease of bone using a simple scoring system: a case control study. , 2007, Bone.

[8]  Jacques P. Brown,et al.  Sequestosome 1: Mutation Frequencies, Haplotypes, and Phenotypes in Familial Paget's Disease of Bone , 2006, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

[9]  R. González-Sarmiento,et al.  -511 C/T IL1B gene polymorphism is associated to resistance to bisphosphonates treatment in Paget disease of bone. , 2006, Bone.

[10]  G. Roodman,et al.  The role of immune cells and inflammatory cytokines in Paget's disease and multiple myeloma , 2005, Immunological reviews.

[11]  E. Porcellini,et al.  Interleukin‐6 gene polymorphism is an age‐dependent risk factor for myocardial infarction in men , 2005, International journal of immunogenetics.

[12]  S. Cummings,et al.  Tumor necrosis factor-alpha polymorphism, bone strength phenotypes, and the risk of fracture in older women. , 2005, The Journal of clinical endocrinology and metabolism.

[13]  D. Rendina,et al.  Interleukin-6 and osteoprotegerin systems in Paget's disease of bone: relationship to risedronate treatment. , 2005, Bone.

[14]  S. Cummings,et al.  Association of the G‐174C Variant in the Interleukin‐6 Promoter Region With Bone Loss and Fracture Risk in Older Women , 2004, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

[15]  G. O’Keefe,et al.  Interleukin-6 Promoter Haplotypes and Interleukin-6 Cytokine Responses , 2003, Shock.

[16]  S. Rendine,et al.  Genotyping for cytokine polymorphisms: allele frequencies in the Italian population. , 2003, European journal of immunogenetics : official journal of the British Society for Histocompatibility and Immunogenetics.

[17]  C. V. van Duijn,et al.  Genetic association studies: genes in search of diseases. , 2002, Neurology.

[18]  Joe C. Adams,et al.  Clinical Implications of Inflammatory Cytokines in the Cochlea: A Technical Note , 2002, Otology & neurotology : official publication of the American Otological Society, American Neurotology Society [and] European Academy of Otology and Neurotology.

[19]  N. Athanasou,et al.  The influence of serum cytokines and growth factors on osteoclast formation in Paget's disease. , 2002, QJM : monthly journal of the Association of Physicians.

[20]  S. Inoue,et al.  A nucleotide variant in the promoter region of the interleukin-6 gene associated with decreased bone mineral density , 2001, Journal of Human Genetics.

[21]  N. Athanasou,et al.  Osteoclast differentiation from circulating mononuclear precursors in Paget's disease is hypersensitive to 1,25-dihydroxyvitamin D(3) and RANKL. , 2000, Bone.

[22]  S. Socransky,et al.  Effect of the interleukin-1 genotype on monocyte IL-1beta expression in subjects with adult periodontitis. , 2000, Journal of periodontal research.

[23]  M. Franceschi,et al.  Association of early‐onset Alzheimer's disease with an interleukin‐1α gene polymorphism , 2000, Annals of neurology.

[24]  R. Pirskanen,et al.  Polymorphisms at −174 and in the 3′ flanking region of interleukin-6 (IL-6) gene in patients with myasthenia gravis , 1999, Journal of Neuroimmunology.

[25]  R. Pirskanen,et al.  Polymorphisms in IL-1β and IL-1 receptor antagonist genes are associated with myasthenia gravis , 1998, Journal of Neuroimmunology.

[26]  E. Siris.  Paget's Disease of Bone , 1991, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

[27]  H. Mcdevitt,et al.  Effects of a polymorphism in the human tumor necrosis factor alpha promoter on transcriptional activation. , 1997, Proceedings of the National Academy of Sciences of the United States of America.

[28]  A. Freemont,et al.  Interleukin‐6, IL‐6 receptor, and IL‐6 nuclear factor gene expression in paget's disease , 1994, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

[29]  F. Coe,et al.  Disorders of bone and mineral metabolism , 1992 .

[30]  A. Blakemore,et al.  Single base polymorphism in the human tumour necrosis factor alpha (TNF alpha) gene detectable by NcoI restriction of PCR product. , 1992, Human molecular genetics.

[31]  G D Roodman,et al.  Interleukin 6. A potential autocrine/paracrine factor in Paget's disease of bone. , 1992, The Journal of clinical investigation.

[32]  D. Resnick.  Diagnosis of Bone and Joint Disorders , 1987 .

[33]  B. Maldague,et al.  Pagets-disease of Bone , 1981 .

[34]  F. Albright,et al.  THE PARATHYROID GLANDS AND METABOLIC BONE DISEASE , 1950, The Ulster Medical Journal.

[35]  L. Wilkins.  Voluntary Medical Care Insurance in the United States , 1949 .

[36]  F. Albright,et al.  The Parathyriod Glands and Metabolic Bone Disease. , 1948 .